Enanta Pharmaceuticals
ENTA
125 hedge funds and large institutions have $552M invested in Enanta Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.
67% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 21
35% more capital invested
Capital invested by funds: $409M → $552M (+$144M)
12% more funds holding
Funds holding: 112 → 125 (+13)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
14% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 42
62% less call options, than puts
Call options by funds: $1.13M | Put options by funds: $2.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Apex Capital Management
Dayton,
Ohio
|
+$24M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11.5M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$8.23M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
-$23.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.89M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$7.39M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$5.45M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$4.8M |
ENTA Hedge Fund Activity: Q4 2014 in Review
125 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2014, worth a combined $552M — up 35% from $409M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ENTA positions and 21 closed out — a net gain of 14 holders — while 36 added to existing stakes and 42 trimmed.
The largest buyer was Apex Capital Management, adding an estimated $24M. The largest seller was Senzar Asset Management, cutting an estimated $23.4M.
- 125 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2014, up from 112 in Q3 2014.
- Funds reported $552M of Enanta Pharmaceuticals stock for Q4 2014, up 35% quarter-over-quarter.
- 35 funds opened new Enanta Pharmaceuticals positions in Q4 2014 and 21 closed out, a net change of +14 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2014 was Apex Capital Management, an estimated $24M added.
- The largest Enanta Pharmaceuticals seller in Q4 2014 was Senzar Asset Management, an estimated $23.4M sold.
Based on aggregated 13F filings for Q4 2014.